Using an antibody to reduce graft-versus-host disease after cord blood transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a special antibody (called a CD25 monoclonal antibody) to the usual transplant regimen can reduce the risk of severe graft-versus-host disease (a common complication where donor cells attack your body) after an umbilical cord blood stem cell transplant for blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer or other malignant blood disease (like leukemia, lymphoma, or myeloma).
- You are going to receive a stem cell transplant using umbilical cord blood.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use effective birth control during treatment and for one year after.
- You have not had a prior stem cell transplant from another person or a solid organ transplant.
- You do not have an uncontrolled bacterial, viral, or fungal infection, and you do not have HIV or active hepatitis B or C.
- You are not pregnant or breastfeeding, and you are able to follow the study requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
This study tests a new medicine called axatilimab, given after a stem cell transplant, to help prevent a common complication called graft-versus-host disease (GVHD), where the donor’s cells attack your body. If you are planning a transplant, this may help improve your recovery.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.